Non-small Cell Lung Cancer
Conditions
Brief summary
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)
Detailed description
The clinical study is a single-arm, phase II, open label, multicenter design in patients with crizotinib-resistant ALK -positive, or crizotinib-resistant/crizotinib-naive ROS1-positive NSCLC.
Interventions
DRUGWX-0593 Tablets
tablets, 60 mg→180mg, quaque die（QD）
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥18 years. 2. Female or male; 3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. 4. Expected survival no less than 12 weeks. 5. Patient should have at least one measurable lesion (RECIST 1.1); Lesions previously treated with radiotherapy can be considered target lesions only if there is a clear evidence of progression after radiotherapy. 6. Histologically or cytologically confirmed advanced ALK-positive NSCLC in upper first-class hospitals，or histologically or cytologically confirmed advanced ROS1-positive NSCLC in a central laboratory. Admission of ROS1-positive patients will be based on the positive test results confirmed by the central laboratory or by the local-approved method. 1. Patients with ALK-positive NSCLC who had been progressive disease after at least 12 weeks of continuous treatment with crizotinib . 2. Patients with ROS1-positive NSCLC who failed in standard treatment (eg.resistant /intolerance of crizotinib or chemotherapy). 3. Patients with ROS1-positive NSCLC who cannot accept chemotherapy. 4. ROS1-positive NSCLC patients who could not afford crizotinib treatment. 7. Patients with or without asymptomatic CNS metastases, or symptomatic brain metastasis after treatment stabilized for more than 4 weeks, and with stopping systemic sex hormone therapy for more than 2 weeks. 8. Organ functions should meet the following requirements (Blood components, cell growth factors, drugs that stimulate the growth of WBC or platelets, or drugs used to correct anemia are not permitted within 14 days prior to the laboratory examination): ANC≥1.5\*10\^9/L PLT≥90\*10\^9/L,Hb≥90 g/L, Total Bilirubin （TBIL）≤1.5\*Upper Limit of Normal（ULN） ( Gilbert's Syndrome TBIL ≤3.0\*ULN and DBIL≤1.5\*ULN )，Alanine Transaminase （ALT）and Aspartate Aminotransferase （AST）≤2.5\*ULN. For liver metastasis patients, ALT and AST≤5\*ULN, Cr≤1.5\*ULN, LVEF≥50%. 9. Any surgery, prior radiotherapy (except for palliative radiotherapy)/procedures must be completed at least 4 weeks prior to starting the treatment with study drug. Palliative radiotherapy must be completed within 48 hours prior to starting treatment. 10. Subject understands and voluntarily provides informed consent.
Exclusion criteria
1. Received any prior ALK inhibitors other than crizotinib. 2. Patients with brain meningeal metastasis. 3. Any clinically significant cardiovascular disease within 6 months prior to the first dose of the investigational drug, including but not limited to: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident (including transient ischemic attack). 4. Two consecutive corrected QT interval (QTc) \> 480 ms through ECG examination during screening, patients with NCI-CTCAE v4.03 Grade ≥2 arrhythmia, Grade ≥2 heart failure, atrial fibrillation and ventricular fibrillation of any grade, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention. 5. Concomitant use of medications that may cause QTc prolongation or induce Torsades de pointes within 14 days prior to the first dose of the investigational drug or during treatment. 6. Continuous use of corticosteroids for more than 30 days, or require chronic use of corticosteroids or other immunosuppressants. 7. Past history of a large area of diffuse/interstitial pulmonary fibrosis, or known history of Grade 3 or 4 interstitial pulmonary fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonitis, interstitial lung disease, obliterative bronchiolitis, or pulmonary fibrosis, but does not include local radiation pneumonitis or radiation-induced pulmonary fibrosis. 8. Patients with Grade \> 1 nausea, vomiting, or diarrhea (CTCAE 4.03), other GI dysfunction or GI disease that may potentially affect drug absorption (such as ulcerative disease or malabsorption syndrome). 9. Subject received other clinical trial treatment within 1 month prior to the first dose of the investigational drug (if the medication received is a marketed drug, then refer to
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Confirmed Objective Response Rate (ORR) Assessed By An Independent Review Committee | From frist administration of WX-0593 to the date that the last patients observed for 18 weeks. | ORR is defined the percentage of the participants who are confirmed to have achieved complete response (CR) or partial response (PR) per an Independent Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after the initiation of study treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | From frist administration of WX-0593 until firstly recorded disease progression or death (whichever occurs earlier), or to the date that the last patients observed for 18 weeks. | PFS defined as the time from baseline to first observed disease progression or death from any cause. |
| Disease Control Rate (DCR) | From frist administration of WX-0593 to the date that the last patients observed for 18 weeks. | DCR is the percentage of patients with best response of CR, PR or Stable Disease (SD). |
| Duration of Response (DOR) | From frist administration of WX-0593 to the date that the last patients observed for 18 weeks . | The DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date on which progressive disease (PD) is first noted or date of death. |
| Time to Progression (TTP) | From frist administration of WX-0593 to the date that the last patients observed for 18 weeks. | Time to Progression |
| Confirmed Objective Response Rate (ORR) Assessed By Investigators | From frist administration of WX-0593 to the date that the last patients observed for 18 weeks. | ORR is defined the percentage of the participants who are confirmed to have achieved complete response (CR) or partial response (PR) per Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after the initiation of study treatment. |
| Overall Survival (OS) | From frist administration of WX-0593 until death due to any cause, withdraws informed consent, is lost to follow-up or refuses phone visits, or study completion（up to 2.5 years） | OS is the time from the start of study treatment to the date of death. |
| Incidence of Adverse Events | the date of written informed consent signed until at least 28 days after the last dose of study drug was administered. | Incidence of All Adverse Events, Serious Adverse Events and Treatment-Emergent Adverse Events by CTCAE v4.03 |
| Cssmin | Pre-dose on Cycle 1 Day 1, Cycle 1 Day 7, Cycle 1 Day 21, Cycle 2 Day 21, and Cycle 4 Day 21 (each cycle is 21 days) | Minimum value of steady plasma-drug concentration for WX-0593 |
| Confirmed Intracranial Objective Response Rate (iORR) | From frist administration of WX-0593 to the date that the last patients observed for 18 weeks. | Confirmed iORR is defined as the proportion of the participants who have achieved CR or PR in the brain per a modification of RECIST version 1.1, after the initiation of study treatment, in participants with intracranial brain metastases at baseline. |
Countries
China
Contacts
Primary ContactShunjiang Yu, CMO
Backup ContactYuankai Shi, M.D
Outcome results
None listed